Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

173.39
Delayed Data
As of Mar 26
 +0.29 / +0.17%
Today’s Change
120.38
Today|||52-Week Range
190.17
+5.90%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$10.5B

Company Description

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded on January 18, 2012 and is headquartered in Dublin, Ireland.

Contact Information

Jazz Pharmaceuticals Plc
Connaught House
Dublin Dublin 4
P:(531) 634-7800
Investor Relations:
(531) 634-7887

Employees

Shareholders

Mutual fund holders63.18%
Other institutional30.36%
Individual stakeholders18.78%

Top Executives

Bruce C. CozaddChairman & Chief Executive Officer
Russell J. CoxChief Operating Officer & Executive Vice President
Matthew P. YoungChief Financial Officer & Executive Vice President
Jeffrey K. TobiasChief Medical Officer, EVP-Research & Development
Mark G. EllerSenior VP-Research & Clinical Development

To view my watchlist

Not a member yet?

Sign up now for a free account